Advertisement

The European Journal of Health Economics

, Volume 13, Issue 4, pp 501–510 | Cite as

A proposed model for economic evaluations of major depressive disorder

  • Hossein Haji Ali AfzaliEmail author
  • Jonathan Karnon
  • Jodi Gray
Original Paper

Abstract

In countries like UK and Australia, the comparability of model-based analyses is an essential aspect of reimbursement decisions for new pharmaceuticals, medical services and technologies. Within disease areas, the use of models with alternative structures, type of modelling techniques and/or data sources for common parameters reduces the comparability of evaluations of alternative technologies for the same condition. The aim of this paper is to propose a decision analytic model to evaluate long-term costs and benefits of alternative management options in patients with depression. The structure of the proposed model is based on the natural history of depression and includes clinical events that are important from both clinical and economic perspectives. Considering its greater flexibility with respect to handling time, discrete event simulation (DES) is an appropriate simulation platform for modelling studies of depression. We argue that the proposed model can be used as a reference model in model-based studies of depression improving the quality and comparability of studies.

Keywords

Economic evaluation Decision modelling Depression Discrete event simulation 

JEL Classification

I18 I19 

Notes

Acknowledgments

This study would not have been possible without the financial support of the Australian Research Council and the South Australia Department of Health. We also thank Justin Beilby, Chris Holton, Adam Elshaug, Barbara Magin, David Banham, Michelle Noort, Wendy Sutton, Adair Garrett for their recommendations.

References

  1. 1.
    Ostin, T.B., Ayuso-Mateos, J.L., Mathers, C., et al.: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 386–392 (2004)CrossRefGoogle Scholar
  2. 2.
    World Health Organisation: The World Health Report 2001. Mental Health: New Understanding New Hope. WHO, Geneva (2002)Google Scholar
  3. 3.
    Guzzetta, F., Tondo, L., Centorrino, F., et al.: Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 68, 380–383 (2007)CrossRefPubMedGoogle Scholar
  4. 4.
    Dumais, A., Lesage, A.D., Alda, M., Rouleau, G., Dumont, M., Chawky, N., Roy, M., Mann, J.J., Benkelfat, C., Turecki, G.: Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am. J. Psychiatry 162, 2116–2124 (2005)CrossRefPubMedGoogle Scholar
  5. 5.
    Wells, K.B., Stewart, A., Hays, R.D., Burnam, M.A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., Ware, J.: The functioning and well-being of depressed patients. Results from the medical outcomes study. JAMA 262, 914–919 (1989)CrossRefPubMedGoogle Scholar
  6. 6.
    Lustman, P.J., Anderson, R.J., Freedland, K.E., et al.: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23, 934–942 (2000)CrossRefPubMedGoogle Scholar
  7. 7.
    Henry, J.A., Rivas, C.A.: Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. Pharmacoeconomics 11, 419–443 (1997)CrossRefPubMedGoogle Scholar
  8. 8.
    Kaplan, W., Laing, R.: Priority Medicines for Europe and the World. WHO, Geneva (2004)Google Scholar
  9. 9.
    Pharmaceutical benefits advisory committee: Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee. Pharmaceutical Benefits Advisory Committee, Canberra (2008)Google Scholar
  10. 10.
    Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: an avoidable fact of life. Health Econ. 6, 217–227 (1997)CrossRefPubMedGoogle Scholar
  11. 11.
    Campbell, H., Briggs, A., Buxton, M., et al.: The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. J. Health Serv. Res. Policy 12, 11–17 (2007)CrossRefPubMedGoogle Scholar
  12. 12.
    Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment: Decision analytic modelling in the economic evaluation of health technologies: a consensus statement. Pharmacoeconomics 17, 443–444 (2000)CrossRefGoogle Scholar
  13. 13.
    Karnon, J., Brown, J.: Selecting a decision model for economic evaluation: a case study and review. Health Care Manag. Sci. 1, 133–140 (1998)CrossRefPubMedGoogle Scholar
  14. 14.
    Nuijten, M.J.: The selection of data sources for use in modelling studies. Phramacoeconomics 13, 305–316 (1998)CrossRefGoogle Scholar
  15. 15.
    Sobocki, P.: Health Economics of Depression. Karolinska Institute, Stockholm (2006)Google Scholar
  16. 16.
    Hylan, T., Buesching, D.P., Tollefson, G.D.: Health economic evaluations of antidepressants: a review. Depress Anxiety 7, 53–64 (1998)CrossRefPubMedGoogle Scholar
  17. 17.
    Jones, M.T., Cockrum, P.C.: A critical review of published economic modelling studies in depression. Pharmacoeconomics 17, 555–583 (2000)CrossRefPubMedGoogle Scholar
  18. 18.
    Frank, L., Revicki, D.A., Sorensen, S.V., et al.: The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 15, 59–83 (2001)CrossRefPubMedGoogle Scholar
  19. 19.
    Iqbal, S.U., Prashker, M.: Pharmacoeconomic evaluation of antidepressants. A critical appraisal of methods. Pharmacoeconomics 23, 595–606 (2005)CrossRefPubMedGoogle Scholar
  20. 20.
    Haji Ali Afzali, H., Karnon, J., Gray, J.: A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources. Pharmacoeconomics (In press)Google Scholar
  21. 21.
    Harris, A., Buxton, M., O’Brien, B., et al.: Using economic evidence in reimbursement decisions for heath technologies: experience of 4 countries. Expert Rev Pharmacoecon Outcomes Res 1, 7–12 (2001)CrossRefPubMedGoogle Scholar
  22. 22.
    Nordstrom, G., Despiegel, N., Marteau, F., et al.: Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J. Med. Econ. 13, 516–526 (2010)CrossRefPubMedGoogle Scholar
  23. 23.
    Sado, M., Knapp, M., Yamauchi, K., et al.: Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust. N. Z. J. Psychiatry 43, 539–547 (2009)CrossRefPubMedGoogle Scholar
  24. 24.
    Simon, J., Pilling, S., Burbeck, R., et al.: Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br. J. Psychiatry 189, 494–501 (2006)CrossRefPubMedGoogle Scholar
  25. 25.
    Sullivan, P.W., Valuck, R., Saseen, J., et al.: A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18, 911–932 (2004)CrossRefPubMedGoogle Scholar
  26. 26.
    François, C., Sintonen, H., Toumi, M.: Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J. Med. Econ. 5, 91–107 (2002)CrossRefGoogle Scholar
  27. 27.
    Lenox-Smith, A., Greenstreet, L., Burslem, K., et al.: Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin. Drug Investig. 29, 173–184 (2009)CrossRefPubMedGoogle Scholar
  28. 28.
    Trivedi, M.H., Wan, G.J., Mallick, R., et al.: Cost and effectiveness of venlafaxine extended-release and SSRIs in the acute phase of outpatient’s treatment for major depressive disorder. J. Clin. Psychopharmacol. 24, 497–506 (2004)CrossRefPubMedGoogle Scholar
  29. 29.
    Armstrong, E.P., Skrepnek, G.H., Haim Erder, M.: Cost–utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr. Med. Res. Opin. 23, 251–258 (2007)CrossRefPubMedGoogle Scholar
  30. 30.
    Benedict, A., Arellano, J., De Cock, E., et al.: Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J. Affect. Disord. 120, 94–104 (2010)CrossRefPubMedGoogle Scholar
  31. 31.
    Armstrong, E.P., Malone, D.C., Haim Erder, M.: A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr. Med. Res. Opin. 24, 1115–1121 (2008)CrossRefPubMedGoogle Scholar
  32. 32.
    Wang, P.S., Patrick, A., Azocar, F., et al.: The costs and benefits of enhanced depression care to employers. Arch. Gen. Psychiatry 63, 1345–1353 (2006)CrossRefPubMedGoogle Scholar
  33. 33.
    Aziz, M., Mehringer, A.M., Mozurkewich, E., et al.: Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Can. J. Psychiatry 50, 389–397 (2005)PubMedGoogle Scholar
  34. 34.
    Sobocki, P., Ekman, M., Ovanfors, A., et al.: The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int. J. Clin. Pract. 62, 623–632 (2008)CrossRefPubMedGoogle Scholar
  35. 35.
    Sobocki, P., Ekman, M., Agren, H., et al.: Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 22, 469–477 (2006)CrossRefPubMedGoogle Scholar
  36. 36.
    Kupfer, D.J.: Long-term treatment of depression. J. Clin. Psychiatry 52, 28–34 (1991)PubMedGoogle Scholar
  37. 37.
    American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder. Am. J. Psychiatry 157, 1–45 (2000)Google Scholar
  38. 38.
    National Institute for Health and Clinical Excellence: Depression: the treatment and management of depression in adults. National Institute for Health and Clinical Excellence (2009)Google Scholar
  39. 39.
    Miller, I.W., Keitner, G.I., Schatzberg, A.F., et al.: The treatment of chronic depression: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59, 608–619 (1998)CrossRefPubMedGoogle Scholar
  40. 40.
    Klein, D.N., Shankman, S.A., Rose, S.: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am. J. Psychiatry 163, 872–880 (2006)CrossRefPubMedGoogle Scholar
  41. 41.
    Satyanarayana, S., Enns, M.W., Cox, B.J., et al.: Prevalence and correlates of chronic depression in the Canadian community health survey: mental health and well-being. Can. J. Psychiatry 54, 389–398 (2009)PubMedGoogle Scholar
  42. 42.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington D.C (1994)Google Scholar
  43. 43.
    Klein, D.N.: Chronic depression: diagnosis and classification. Curr. Dir. Psychol. Sci. 19, 96–100 (2010)CrossRefGoogle Scholar
  44. 44.
    Rowe, S.K., Rapaport, M.H.: Classification and treatment of sub-threshold depression. Curr. Opin. Psychiatry 19, 9–13 (2006)CrossRefPubMedGoogle Scholar
  45. 45.
    Keller, M.B., Kleman, G.L., Lavori, P.W., et al.: Long-term outcome of episodes of major depression. JAMA 252, 788–792 (1998)CrossRefGoogle Scholar
  46. 46.
    McCullough, J.P., Kornstein, S.G., McCullough, P., et al.: Differential diagnosis of chronic depressive disorders. Psychiatr. Clin. North Am. 19, 55–71 (1996)CrossRefPubMedGoogle Scholar
  47. 47.
    Fineberg, H.V.: Decision trees: construction, uses, and limits. Bull. Cancer 67, 395–404 (1980)PubMedGoogle Scholar
  48. 48.
    Klein, R.W., Dittus, R.S., Roberts, S.D., et al.: Simulation modelling and health care decision making. Med. Decis. Making 13, 347–354 (1993)CrossRefPubMedGoogle Scholar
  49. 49.
    Hardeveld, F., Spijker, J., De Graaf, R., et al.: Prevalence and predicators of recurrence of major depressive disorder in the adult population. Acta Psychiatr. Scand. 122, 184–191 (2010)CrossRefPubMedGoogle Scholar
  50. 50.
    Lewinsohn, P.M., Rohde, P., Seeley, J.R., et al.: Natural course of adolescent major depressive disorder in community sample: predicators of recurrence in young adults. Am. J. Psychiatry 157, 1584–1591 (2000)CrossRefPubMedGoogle Scholar
  51. 51.
    Conradi, H.J., Jonge, P., Ormel, J.: Prediction of the three-year course of recurrent depression in primary care patients: different risk factors for different outcomes. J. Affect. Disord. 105, 267–271 (2008)CrossRefPubMedGoogle Scholar
  52. 52.
    Marcus, S.M., Young, E.A., Kerber, K.B., et al.: Gender differences in depression: findings from the STAR*D study. J. Affect. Disord. 87, 141–150 (2005)CrossRefPubMedGoogle Scholar
  53. 53.
    Karnon, J.: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 12, 837–848 (2003)CrossRefPubMedGoogle Scholar
  54. 54.
    Le Lay, A., Despiegel, N., Francois, C., et al.: Can discrete event simulation be of use in modelling major depression? Cost Eff. Resour. Alloc. 4, 19 (2006)CrossRefPubMedGoogle Scholar
  55. 55.
    Banks, J., Carson, J.S., Nelson, B.L., et al.: Discrete Event System Simulation, 5th edn. Prentice-Hall, New Jersey (2010)Google Scholar
  56. 56.
    Khan, A., Khan, S.R., Shankles, E.B., et al.: Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials. Int. Clin. Psychopharmacol. 17, 281–285 (2002)CrossRefPubMedGoogle Scholar
  57. 57.
    Nierenberg, A., De Cecco, L.M.: Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62, (Suppl) 5–9 (2001)Google Scholar
  58. 58.
    Frank, E., Prien, R.F., Jarrett, R.B., et al.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch. Gen. Psychiatry 48, 851–855 (1991)CrossRefPubMedGoogle Scholar
  59. 59.
    Zimmerman, M., Posternak, M., Chelminski, I.: Defining remission on the Montgomery-Asberg depression rating scale. J. Clin. Psychiatry 65, 163–168 (2004)CrossRefPubMedGoogle Scholar
  60. 60.
    Geddes, J.R., Carney, S.M., Davies, C., et al.: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661 (2003)CrossRefPubMedGoogle Scholar
  61. 61.
    Pliskin, J.S., Tell, E.J.: A dialysis need forecasting model: a retrospective evaluation. Med. Decis. Making 3, 489–500 (1983)CrossRefPubMedGoogle Scholar
  62. 62.
    Harris, A., Bulfone, L.: Getting value for money: the Australian experience. In: Jost, T.S., (ed.) Health care Coverage Determinations: An International Comparative Study, pp. 25–56. Open University Press, Maidenhead, UK (2005)Google Scholar
  63. 63.
    Halpern, M.T., Luce, B.R., Brown, R.E., et al.: Health and economic outcomes modelling practices: a suggested framework. Value Health 1, 131–147 (1998)CrossRefPubMedGoogle Scholar
  64. 64.
    Sculpher, M., Fenwick, E., Claxton, K.: Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 17, 461–477 (2000)CrossRefPubMedGoogle Scholar
  65. 65.
    Sheldon, T.A.: Problems of using modelling in the economic evaluation of health care. Health Econ. 5, 1–11 (1996)CrossRefPubMedGoogle Scholar
  66. 66.
    UKPDS Outcomes Model. http://www.dtu.ox.ac.uk/outcomesmodel/. Accessed 11 April 2011
  67. 67.
    Weinstein, M.C., O’Brien, B., Hornberger, J., et al.: Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR task force on good research practices—modelling studies. Value Health 6, 9–17 (2003)CrossRefPubMedGoogle Scholar
  68. 68.
    Eddy, D.M., Schlessinger, L.: Validation of the Archimedes diabetes model. Diabetes Care 26, 3102–3110 (2003)CrossRefPubMedGoogle Scholar
  69. 69.
    Primary Care Services Improvement Project. http://www.adelaide.edu.au/pcsip/(2009). Accessed 29 January 2011
  70. 70.
    Beilby, J., Marley, J., Walker, D., et al.: Effects of changes in antibiotic prescribing on patient outcomes in a community setting: a natural experiment. Clin. Infect. Dis. 34, 55–64 (2002)CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Hossein Haji Ali Afzali
    • 1
    Email author
  • Jonathan Karnon
    • 1
  • Jodi Gray
    • 1
  1. 1.Discipline of Public HealthThe University of AdelaideAdelaideAustralia

Personalised recommendations